Evaluation of preoperative non-invasive ventilation in thoracic surgery for lung cancer: The preOVNI study GFPC 12-01 [Évaluation de la ventilation non invasive préopé ratoire avant chirurgie de résection pulmonaire. Étude préOVNI GFPC 12-01]
Paleiron N.,Service des Maladies Respiratoires |
Andre M.,Service des Maladies Respiratoires |
Grassin F.,Service des Maladies Respiratoires |
Chouaid C.,Service de pneumologie |
And 16 more authors.
Revue des Maladies Respiratoires | Year: 2013
Background. - Surgical resection is the best treatment for stage I and II non-small cell lung cancer. Despite an improvement in the perioperative management of cancer patients and specialization of surgical teams, morbidity and mortality remains significant. Non-invasive ventilation (NIV) is an effective therapeutic option in hypercapnic respiratory failure. It also improves functional and gasometric parameters when undertaken before surgery. The objective of the preOVNI study is to demonstrate that preoperative non-invasive ventilation for 7 days, at home, reduces the postoperative respiratory and cardiovascular complications of lung resection surgery, in a high-risk population. Methods. - A prospective, randomized, controlled open-labelled multicentric French study, under the supervision of the Groupe Français de Pneumocancérologie (GFPC), comparing 7 days of preoperative non-invasive ventilation with standard treatment. Inclusion criteria are: patients suitable for lobectomy or segmentectomy for primary bronchial carcinoma and presenting with obstructive or restrictive lung disease, obesity or chronic cardiac insufficiency. The primary criterion is a composite one, including all respiratory and cardiac complications. The number of patients is 150 in each treatment arm, 300 in total. Expected results. - We think that preoperative NIV will be able to reduce the rate of postoperative complications. If this objective is achieved, the management of these patients could be changed. © 2012 SPLF. Published by Elsevier Masson SAS. All rights reserved. Source
Assessment of daily physical activity of breast cancer patients and comparison with two control populations [Quantification de l'activité physique journalière des patientes traitées pour un cancer du sein et comparaison avec deux populations témoins]
Guichard J.-B.,Institute Cancerologique Of La Loire |
Garet M.,Jean Monnet University |
Auberdiac P.,Institute Cancerologique Of La Loire |
Nourissat A.,Institute Cancerologique Of La Loire |
And 10 more authors.
Bulletin du Cancer | Year: 2011
Objective. The purpose is to assess the physical activity of breast cancer patients using a questionnaire, the Population Physical Activity Questionnaire (POPAQ) and to compare the data with those from two female populations: one healthy population and one with a previous history of cardiovascular disease. Patients and methods. This prospective study included 104 consecutive breast cancer patients who were addressed at the radiation oncology department, Institut de cancérologie de la Loire from March to July 2010. A questionnaire using factorial method was used for assessment of physical activity. Results. In the study population, the rest energetic expenditures of physical energy related to both rest activity and low intensity activity were higher than in the healthy patients (5 292±1 376 versus 5 520±1 248 kJ/24 h, P<0.05 and 2 583±681 versus 2 494±558 kJ/24 h, P<0.05, respectively). Conversely, the energetic expenditures of physical energy related to both high physical activity and intensive physical activity were lower than in the healthy population (882±441 versus 1 560±868 kJ/24 h, P<0.05 et 210±274 versus 340±621 kJ/24 h, P<0.05, respectively). Conclusion. The POPAQ allows quantifying the daily physical activity and seems feasible in clinical routine in breast cancer patients. In our study, it was found that the physical activity of those patients was significantly different from that of a healthy population. Further investigations are necessary for better defining the true impact of such differences in terms of incidence and prognostic for mammary carcinoma. ©John Libbey Eurotext. Source
Merlin E.,Service de pediatrie |
Merlin E.,French Institute of Health and Medical Research |
Mouy R.,Unite Dimmunologie |
Pereira B.,Service de pediatrie |
And 12 more authors.
Joint Bone Spine | Year: 2015
Objective: To assess the prognostic impact of clinical presentation in children with polyarteritis nodosa (PAN). Methods: Children diagnosed between 1986 and 2006 in a tertiary care pediatric rheumatology center were classified as "cutaneous PAN" (group 1), "cutaneous PAN with significant extra-cutaneous features" (group 2) or "visceral childhood PAN" (group 3). Outcome measures: (1) clinical remission off-therapy at last follow-up, (2) requirement and length of glucocorticoid therapy, (3) presence of disease-related sequelae. Results: Twenty-nine children were included. Sixteen met the Ankara criteria for PAN. Nine patients were qualified as group 1, 11 as group 2, and 9 as group 3. At last follow-up, 15 children were in clinical remission off-therapy: 4 from group 1 (44%), 4 from group 2 (36%) and 7 from group 3 (78%). Glucocorticoid therapy was required for 8 (89%), 7 (64%) and 7 (78%) patients from groups 1, 2 and 3, respectively. Seven children did not require any glucocorticoid therapy. Time-dependent probability of achieving glucocorticoid-free clinical remission was similar between the three groups. Three patients (one from each group) had digital ischemia leading to amputation. There were no significant between-group differences in outcome based on the three outcome measures addressed. Conclusion: Outcome was not strikingly predictable from initial presentation in children with PAN. The organ distribution-based distinction between cutaneous and visceral PAN had little prognostic power in this series. © 2015. Source
Reappraisal of the role of hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of ovarian cancer: A single institutional experience [Place de la chimiothérapie hyperthermique intrapé ritonéale (CHIP) dans la prise en charge du cancer de l'ovaire: Expérience monocentrique institutionnelle]
Melis A.,Institute Cancerologique Of La Loire |
Abboud K.,CHU de Saint Etienne |
Bourmaud A.,Institute Cancerologique Of La Loire |
Pacaut C.,Institute Cancerologique Of La Loire |
And 5 more authors.
Bulletin du Cancer | Year: 2011
The peritoneal carcinomatosis of ovarian cancer led to the development of optimal cytoreduction surgery completed by hyperthermic intraperitoneal chemotherapy (HIPEC). The main goal of this study is to evaluate the feasibility, tolerance and efficacy of this technique in patients with ovarian cancer. A retrospective monocentric study has evaluated 43 patients with HIPEC procedures from 1995 to 2009. After a complete cytoreduction surgery, a HIPEC procedure with cisplatin is performed. Data on complications and survival parameters were collected. Prognostic factors were also analyzed. Post-surgery complications included one death due to a septic shock (2.3%) and six patients have presented major complications (13.9%). The median of overall survival and progression free survival were 53.6 and 39 months, respectively. Patients with a primary complete surgical cytoreduction of the peritoneal carcinomatosis presented overall survival length of 131 months versus 84 months without initial complete resection (P < 0.0001). Surgical cytoreduction combined with HIPEC is a feasible procedure with acceptable morbid-mortality rates. The initial complete resection of the peritoneal carcinomatosis significantly increases survival and represents a strong prognostic factor. ©John Libbey Eurotext. Source